Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results : vimarsana.com

Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million



Full Year 2023 Core Revenue grows 44% year-over-year to $262.1 million; Q4 2023 Core Revenue grows 21%...

Related Keywords

United States , America , Paul Kim , Ming Hsieh , Fulgent Genetics Inc , Nasdaq , Exchange Commission , Fulgent Genetics , Core Revenue , Chief Executive Officer , Precision Diagnostics , Investigational New Drug , Chief Financial Officer , Investor Relations , Private Securities Litigation Reform Act , Beacon Expanded Carrier , Consolidated Statement , Twelve Months Ended December , Months Ended December , Markets ,